Literature DB >> 4272473

Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.

H L Davis, G Ramirez, F J Ansfield.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4272473     DOI： 10.1002/1097-0142(197401)33:1<193::aid-cncr2820330128>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  10 in total

1.  Primary hepatocellular carcinoma--recent advances and future prospects.

Authors: 
Journal:  West J Med       Date:  1985-10

2.  Clinical decision analysis using microcomputers. A case of coexistent hepatocellular carcinoma and abdominal aortic aneurysm.

Authors:  J B Wong; A J Moskowitz; S G Pauker
Journal:  West J Med       Date:  1986-12

3.  Tissue sampling from the common bile duct through endoscopic retrograde cholangiopancreatography, endoscopic papillo(sphinctero)tomy and drainage in juxtapapillary malignancies.

Authors:  V Pugliese; D Barone; S Saccomanno; M Conio; H Aste; L Santi
Journal:  Surg Endosc       Date:  1987       Impact factor: 4.584

4.  High-dose mitomycin C: activity in hepatocellular carcinoma.

Authors:  A Cheirsilpa; S Leelasethakul; V Auethaveekiat; S Maoleekulpriroj; N Kangsumrit; P Thanakaravit; P Phanthumjida
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.

Authors:  Kerry J Williams; Joel Picus; Kim Trinkhaus; Chloe C Fournier; Rama Suresh; Joan S James; Benjamin R Tan
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

6.  Primary adenocarcinoma of the bile ducts. Clinical characteristics and natural history.

Authors:  J T Bruggen; M S McPhee; P S Bhatia; J M Richter
Journal:  Dig Dis Sci       Date:  1986-08       Impact factor: 3.199

7.  Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.

Authors:  Myung Ah Lee; In Sook Woo; Jin-Hyoung Kang; Young Seon Hong; Kyung Shik Lee
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-28       Impact factor: 4.553

8.  Hepatoma/merbarone. A Southwest Oncology Group study.

Authors:  E A Poplin; C M Tangen; W H Harvey; J S Macdonald
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.

Authors:  J S Graham; K Boyd; F Y Coxon; L R Wall; M M Eatock; T S Maughan; M Highley; E Soulis; S Harden; P Bützberger-Zimmerli; T R J Evans
Journal:  BMC Res Notes       Date:  2016-03-12

10.  Capecitabine plus Oxaliplatin as a Second-Line Therapy for Advanced Biliary Tract Cancers: A Multicenter, Open-Label, Phase II Trial.

Authors:  Seung Tae Kim; Sung Yong Oh; Jeeyun Lee; Jung Hun Kang; Hyun Woo Lee; Myung Ah Lee; Byeong Seok Sohn; Ji Hyong Hong; Young Suk Park; Joon Oh Park; Ho Yeong Lim
Journal:  J Cancer       Date:  2019-10-15       Impact factor: 4.207
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.